藥康生物(688046.SH):江西中洪擬引入投資者蘇州濟康、蘇州國發
格隆匯9月27日丨藥康生物(688046.SH)公佈,公司參股公司江西中洪博元生物技術有限公司(“江西中洪”)擬增加註冊資本人民幣59.5238萬元並引入投資者。
為解決研發投入資金需求,加快推動疾病動物模型研發進度和產業化步伐,公司近日與江西中洪、增資方蘇州濟康創業投資合夥企業(有限合夥)(“蘇州濟康”)以及蘇州國發科技創新投資企業(有限合夥)(“蘇州國發”)簽署《股權增資認購協議》,江西中洪擬將其註冊資本從人民幣625萬元增加至人民幣684.5238萬元,蘇州濟康以人民幣3800萬元投資款認繳江西中洪新增註冊資本45.2381萬元,蘇州國發以人民幣1200萬元投資款認繳江西中洪新增註冊資本14.2857萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.